ELIOS Announces New Research Results Visit our Press Room →

Our Clinical Experience

Dedicated to Developing Breakthrough Treatments

There remains a need to create a host active specific immune response, generating an army of tumor reactive T-cells that can attack a patient’s disease alone and improve the outcomes for patients on therapies that manipulate T cells in the adjuvant and metastatic settings.

TLPLDC Phase 2 Data Summary

In a pre-specified interim analysis, data were recently presented from prospective, randomized, double-blinded, placebo-controlled Phase 2b trial evaluating TLPLDC therapy compared to placebo in patients with resected Stage III and IV melanoma.

Safe & Tolerable

  • TLPLDC is safe with minimal toxicity – no greater than Grade 2 adverse events
  • Data and Safety Monitoring Board recommended the study continue as planned

Encouraging Clinical Responses

  • Some subsets already statistically significant
  • Topline Phase 2b data anticipated Q2 2019

Data Presentations

Download our most recent research findings ›

Trial Affiliations

ELIOS has forged partnerships with leading research institutions around the United States. Our goal is to continue to expand the experience and effectiveness of our novel approach to personalized therapeutic cancer vaccines.


(Trademarks listed above, registered or unregistered, are the property of their respective owners.)